Safiya AlShamsi
Research Subjects
Research Interests
Safiya AlShamsi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Asma Fikri
Public Health Sector , Ministry of Health and Prevention, P.O. Box 1853, Dubai , UAE
1 shared publication - Fatima Alshehhi
Public Health Sector , Ministry of Health and Prevention, P.O. Box 1853, Dubai , UAE
1 shared publication - Habiba Alsafar
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, UAE
1 shared publication - Hussain Al Rand
Public Health Sector , Ministry of Health and Prevention, P.O. Box 1853, Dubai , UAE
1 shared publication - Mira Mousa
Center for Biotechnology , Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi , UAE
1 shared publication - Mohammed Albreiki
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Biosecurity Affairs Division, Innovation and Development Sector, Abu Dhabi Agriculture and Food Safety Authority, Abu Dhabi, United Arab Emirates
1 shared publication
Latest Publications
- Open Access
- 4 March 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (6)
Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE
The UAE implemented swift and proactive mitigation measures to combat the COVID-19 pandemic. While there are currently five primary approved vaccines in the UAE, inactivated vaccine BBIBP-CorV (Sinopharm), which has a 78% effectiveness in preventing hospitalization due to COVID-19 infections, 1 and mRNA vaccine BNT162b2 (Pfizer-BioNTech), with an effectiveness at 93% in preventing hospitalization due to COVID-19 infections, 2 are most commonly administered. Due to the successful early COVID-19 vaccination rollout, ~91.6% of the population has been vaccinated, which is mainly attributed to a model governance system, logistical capabilities, accessibility and delivery, digital infrastructure and vaccine manufacturing facility. 3
- 4 March 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (6)
Open AccessSimilar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE
The UAE implemented swift and proactive mitigation measures to combat the COVID-19 pandemic. While there are currently five primary approved vaccines in the UAE, inactivated vaccine BBIBP-CorV (Sinopharm), which has a 78% effectiveness in preventing hospitalization due to COVID-19 infections, 1 and mRNA vaccine BNT162b2 (Pfizer-BioNTech), with an effectiveness at 93% in preventing hospitalization due to COVID-19 infections, 2 are most commonly administered. Due to the successful early COVID-19 vaccination rollout, ~91.6% of the population has been vaccinated, which is mainly attributed to a model governance system, logistical capabilities, accessibility and delivery, digital infrastructure and vaccine manufacturing facility. 3